Nivolumab verbetert overleving van HCC-patiënten

Delen via:
AASLD 2017

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Sangro B, Melero I, Yau T, et al. Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040. AAASLD 2017, Presidential Poster of Distinction 141.